GLP1减重宝典·2026-03-27 08:15Core Viewpoint - The expiration of the core compound patent for Semaglutide in China marks the transition of competition from clinical and application stages to a more sensitive market launch phase, with at least 10 domestic companies having submitted registration applications, indicating a shift from a multi-point battle to a more concentrated front [5] Group 1: Competitive Landscape - The competition for Semaglutide in China is not merely a race for first generics; it involves different registration pathways, with companies like Jiuyuan Gene and Lizhu Group following a 3.3 category approach, while Qilu Pharmaceutical and Baike Bio are pursuing a 2.2 category path for potentially faster review processes [5] - Qilu Pharmaceutical and Baike Bio are currently the most prominent competitors, with Qilu having its application accepted in September 2024 and Baike advancing both diabetes and weight management indications to the application stage [6] - Jiuyuan Gene, while initially a front-runner, faced setbacks with some specifications not passing review, but it remains competitive due to its early start and comprehensive coverage of both diabetes and weight management [8] Group 2: Market Dynamics - The competition has bifurcated into two lines: the more mature diabetes indication market and the smaller but rapidly growing weight management indication market, with only Baike Bio and Jiuyuan Gene having received acceptance for weight management applications so far [9] - The significance of the first approval extends beyond mere timing; it encompasses the ability to convert that approval into production capacity, pricing, hospital access, and patient education, which are critical for establishing market presence [9] - The narrative surrounding Semaglutide in China is evolving from a simple race for generics to a complex competition focused on registration classification, review efficiency, and commercialization capabilities [9]